Literature DB >> 2439794

Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.

K U Bühring, H Sailer, H P Faro, G Leopold, J Pabst, A Garbe.   

Abstract

The pharmacokinetic properties of bisoprolol-14C were studied in Wistar rats, beagle dogs, and Cynomolgus monkeys. Bisoprolol is well absorbed in these species; independent of the route of administration (i.v. or p.o.), 70-90% of the 14C-dose was recovered in urine. Faecal excretion was approximately 20% in rats and less than 10% in dogs and monkeys. Rats excreted approximately 10% of the dose in bile after i.v. as well as after oral administration. The plasma half-life of the unchanged drug was approximately 1 h in rats, 3 h in monkeys, and 5 h in dogs. The bioavailability was 40-50% in monkeys, approximately 80% in dogs, and 10% in rats. Studies in rats have shown that the drug is rapidly taken up by the tissues. After i.v. administration, high levels of radioactivity were found in lung, kidneys, liver, adrenals, spleen, pancreas, and salivary glands. After oral administration, the highest concentration occurred in the liver and kidneys. With the exception of plasma and liver, unchanged bisoprolol was the major radioactive constituent in all tissues studied. Both the blood-brain and placental barriers were penetrated, but only to a small degree. No accumulation of radioactivity in tissues was observed after repeated dosing (1 mg/kg/day). The metabolism of bisoprolol was studied in the same three animal species and in humans. The major metabolites are the products of O-dealkylation and subsequent oxidation to the corresponding carboxylic acids. The amount of bisoprolol excreted unchanged in the urine is 50-60% of the dose in humans, 30-40% in dogs, and approximately 10% in rats and monkeys.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2439794     DOI: 10.1097/00005344-198511001-00004

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  9 in total

Review 1.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

Review 2.  Clinical pharmacokinetics of drugs in patients with heart failure: an update (part 2, drugs administered orally).

Authors:  Ryuichi Ogawa; Joan M Stachnik; Hirotoshi Echizen
Journal:  Clin Pharmacokinet       Date:  2014-12       Impact factor: 6.447

3.  β-Blocker Dialyzability in Maintenance Hemodialysis Patients: A Randomized Clinical Trial.

Authors:  Alvin Tieu; Thomas J Velenosi; Andrew S Kucey; Matthew A Weir; Bradley L Urquhart
Journal:  Clin J Am Soc Nephrol       Date:  2018-03-08       Impact factor: 8.237

4.  Microbial metabolism of the beta-adrenoreceptor antagonist bisoprolol.

Authors:  H Schwartz; R E Licht; H E Radunz
Journal:  Appl Microbiol Biotechnol       Date:  1993-11       Impact factor: 4.813

5.  Population pharmacokinetic analysis of bisoprolol.

Authors:  J Grevel; P Thomas; B Whiting
Journal:  Clin Pharmacokinet       Date:  1989-07       Impact factor: 6.447

6.  Effects of acute febrile infectious diseases on the oral pharmacokinetics and effects of nitrendipine enantiomers and of bisoprolol.

Authors:  P A Soons; C Grib; D D Breimer; W Kirch
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

7.  Novel selective β1-adrenoceptor antagonists for concomitant cardiovascular and respiratory disease.

Authors:  Jillian G Baker; Sheila M Gardiner; Jeanette Woolard; Christophe Fromont; Gopal P Jadhav; Shailesh N Mistry; Kevin S J Thompson; Barrie Kellam; Stephen J Hill; Peter M Fischer
Journal:  FASEB J       Date:  2017-04-11       Impact factor: 5.191

8.  Application of physiologically based biopharmaceutics modeling to understand the impact of dissolution differences on in vivo performance of immediate release products: The case of bisoprolol.

Authors:  Joyce S Macwan; Grace Fraczkiewicz; Mauro Bertolino; Phillip Krüger; Sheila-Annie Peters
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2021-06-03

Review 9.  Examination of Urinary Excretion of Unchanged Drug in Humans and Preclinical Animal Models: Increasing the Predictability of Poor Metabolism in Humans.

Authors:  Nadia O Bamfo; Chelsea Hosey-Cojocari; Leslie Z Benet; Connie M Remsberg
Journal:  Pharm Res       Date:  2021-07-12       Impact factor: 4.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.